Mike Robinson, Founder Global Cannabinoid Research Center, specializes in researching our own bodies Cannabinoids and the ECS David Uhalley ...

The poster is scheduled for presentation on May 31, 2025, from 01:30pm to 04:30pm CDT in the Lung Cancer track. "We continue to believe that our telomere targeting agent ateganosine (THIO) could ...

Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced its slate of seven scientific presentations, three oral and four in poster form, that have been accepted for the 28th Annual ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting, scheduled for May 30 to June ...

Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...

The max poster file size is 6MB. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. All submitted posters will be reviewed, and ...

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to ...

A new assessment strategy Last academic year, after a discussion with my head of department, I arranged a poster presentation assessment. This required students to work in pairs and design a poster ...

A second poster presentation related to the OnTarget trial, based on data from the placebo arm of the study, will also take place during Poster Session 1 at SABCS on December 11, 2024. In addition ...

Poster Presentations Title: A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC ...